| Cash flow (USD) | FY 2026 ended Jun 30, 2026 | FY 2025 ended Jun 30, 2025 | FY 2024 ended Jun 30, 2024 | FY 2023 ended Jun 30, 2023 | FY 2022 ended Jun 30, 2022 | FY 2021 ended Jun 30, 2021 |
|---|---|---|---|---|---|---|
| Net income | -18.86M | -58.92M | -1.82M | -2.66M | -2.66M | -2.03M |
| Depreciation and amortization | 997 | 297 | 1.7K | 2.0K | 2.0K | |
| Stock-based compensation | 8.50M | 4.62M | 2.4K | 72.5K | 82.9K | |
| Cash from operations | -5.68M | -405.2K | -935.1K | -1.11M | -1.44M | -1.15M |
| Capital expenditure | -4.9K | |||||
| Free cash flow | -5.69M | |||||
| Cash from investing | -4.9K | |||||
| Net debt issued | -671.8K | -122.8K | ||||
| Cash from financing | 6.46M | 490.8K | 941.9K | 1.11M | 1.49M | 1.06M |
| Net change in cash | 819.9K | -9.0K | 11.0K | 6.0K | 1.8K | -64.8K |
From Propanc Biopharma, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.